



07-29-04

IFW

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/726,168
	Filing Date	December 2, 2003
	First Named Inventor	Magid A. Abou-Gharbia
	Art Unit	1614
	Examiner Name	Not Assigned
Total Number of Pages in This Submission	Attorney Docket Number	WYTH0107-100(AM100146C2)

ENCLOSURES (check all that apply)				
<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/ Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application <input checked="" type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Technology Center (TC)  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  <b>Table A with above-referenced application highlighted and copy of Assignment.</b>		
<table border="1"><tr><td>Remarks</td></tr><tr><td>VIA EXPRESS MAIL LABEL NO. EV147609110US DATE SENT: JULY 28, 2004  <b>EV147609110US</b></td></tr></table>			Remarks	VIA EXPRESS MAIL LABEL NO. EV147609110US DATE SENT: JULY 28, 2004  <b>EV147609110US</b>
Remarks				
VIA EXPRESS MAIL LABEL NO. EV147609110US DATE SENT: JULY 28, 2004  <b>EV147609110US</b>				

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Michael P. Straher/38,325
Signature	
Date	July 28, 2004

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name			
Signature		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**POWER OF ATTORNEY WITH REVOCATION AND  
CHANGE OF CORRESPONDENCE ADDRESS**

I hereby revoke all previous powers of attorney or authorizations of agent given in the applications identified in Table A attached hereto, and appoint

☒ Practitioners at Customer Number: **35139**

PLACE CUSTOMER NUMBER BAR  
CODE LABEL HERE

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please change the Correspondence Address for all applications identified in Table

A to:

☒ Practitioners at Customer Number: **35139**

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. (A statement under 37 CFR 3.73(b) is enclosed.)

Respectfully submitted,

WYETH

Date: 7/31/03

By: 

Name: William H. Calnan  
Title: Assistant Secretary



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant, Wyeth (formerly known as American Home Products Corporation),  
a corporation, states that it is:

☒ the assignee of the entire right, title, and interest of the applications identified in  
Table A attached hereto.

The extent (by, percentage) of its ownership interest is 100% in the patent applications  
identified in Table A by virtue of:


☒ a copy of the pertinent assignment from the inventor(s) of the patent applications  
identified in Table A is enclosed herewith.

The undersigned (whose title is supplied below) is authorized to act on behalf of the  
assignee.

Respectfully submitted,

WYETH

Date: 7/31/03

By: 

Name: William H. Calnan

Title: Assistant Secretary

AM-100146  
PATENTSERIAL NO. 09/711.793FILED NOVEMBER 10, 2000ASSIGNMENT

WHEREAS we

- (1) Magid A. Abou-Gharbia
- (2) James E. Barrett
- (3) Wayne E. Childers, Jr.
- (4) John A. Moyer

residing, respectively, at:

	<u>TOWN OR CITY:</u>	<u>IN THE COUNTY OF:</u>	<u>AND IN THE STATE OF:</u>
(1)	Princeton Junction	Mercer	New Jersey
(2)	Washington Crossing	Bucks	Pennsylvania
(3)	New Hope	Bucks	Pennsylvania
(4)	New Hope	Bucks	Pennsylvania

have invented certain new and useful Improvements in

METHODS FOR THE TREATMENT AND PREVENTION  
OF NEURODEGENERATIVE CONDITIONS

for which we have, respectively, on:

- (1) the 10<sup>th</sup> day of November, 2000,
- (2) the 10<sup>th</sup> day of November, 2000,
- (3) the 10<sup>th</sup> day of November, 2000,
- (4) the 10<sup>th</sup> day of November, 2000,

executed an application for Letters Patent of the United States, the date of filing and serial number of said application, when known to be inserted above; and

AHP-97393  
PATENT

WHEREAS, AMERICAN HOME PRODUCTS CORPORATION, a corporation duly organized and existing under the laws of the State of Delaware, and having a place of business at Five Giralda Farms, in the County of Morris, and State of New Jersey, hereinafter called ASSIGNEE, is desirous of acquiring the entire right, title and interest in and to said invention, in the United States of America, its territories, dependencies and possessions, and in all foreign countries, and in and to any United States or foreign Letters Patent that may be granted therefor, and in and to such other forms of protection of industrial property as may be granted therefor pursuant to the laws of any country:

NOW, THEREFORE, in consideration of ONE DOLLAR (\$1.00) in hand paid to each of us, and other good and valuable considerations, the receipt of which is hereby acknowledged, we by these presents, have sold, assigned and transferred, and do hereby sell, assign and transfer, to ASSIGNEE, its successors, legal representatives and assigns, the entire right, title and interest in and to the said invention, in the United States of America, its territories, dependencies and possessions, and in all foreign countries, in and to any subsequently filed provisional or nonprovisional patent application of the United States, and in and to any Letters Patent of the United States and foreign countries (including all divisions, reissues, continuations and extensions thereof) that may be granted therefor, and in and to such other forms of protection of industrial property as may be granted therefor pursuant to the laws of any country, and the right to apply for Letters Patent and such other forms of protection of industrial property as may be provided by any country, with full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty or by international convention, together with the right to extend the protection of said United States Letters Patent to territorial possessions now owned or which may hereafter be acquired by the United States of America, for the full term for which said Letters Patent or said other forms of protection may be granted;

And we covenant and agree with ASSIGNEE that we have a full and unencumbered title to the invention hereby assigned, which title we warrant to ASSIGNEE;

And we further agree that we will, at ASSIGNEE's request, without demanding further consideration therefor but entirely at ASSIGNEE's expense, do all lawful and just acts, including the execution and acknowledgement of instruments, that may be or become necessary for obtaining, sustaining or reissuing United States and foreign Letters Patent or said other forms of protection covering the invention hereby assigned, and for maintaining and perfecting ASSIGNEE's right to said invention, Letters Patent and other forms of protection, particularly in cases of interference and litigation.

AHP-97393  
PATENT

IN WITNESS WHEREOF, we have respectively, hereunto set our hands and seals:

- (1) this 10<sup>th</sup> day of November, 2000
- (2) this 10<sup>th</sup> day of November, 2000
- (3) this 10<sup>th</sup> day of November, 2000
- (4) this 10<sup>th</sup> day of November, 2000

(1) Magid A. Abou-Gharbia (L.S.)  
Magid A. Abou-Gharbia

WITNESS AS TO (1):

Elizabeth Melick  
Marie Arcaro

(2) James E. Barrett (L.S.)  
James E. Barrett

WITNESS AS TO (2):

Elizabeth Melick  
Marie Arcaro

(3) Wayne E. Childers, Jr. (L.S.)  
Wayne E. Childers, Jr.

WITNESS AS TO (3):

Elizabeth Melick  
Marie Arcaro

AHP-97393  
PATENT(4) John A. Moyer (L.S.)  
John A. Moyer


WITNESS AS TO (4):

Elizabeth Muck  
Marie ArcaroSTATE OF NEW JERSEY )  
: SS:  
COUNTY OF MIDDLESEX )On this 10<sup>th</sup> day of November, 2000, before me personally  
appeared

- (1) Magid A. Abou-Gharbia
- (2) James E. Barrett
- (3) Wayne E. Childers, Jr.
- (4) John A. Moyer

to me known and known to me to be the individuals described in and who executed  
the foregoing instrument, and they acknowledged to me that they executed the same.

Barbara L. Lences  
Notary Public  
BARBARA L. LENCES  
Notary Public of New Jersey  
My Commission Expires Dec. 14, 2002



# TABLE A

SERIAL NO.	FILING DATE	INVENTORS	EXAMINER	ART UNIT	TITLE
60/283,387	April 12, 2001	Failli, Shumsky, Dusza, Caggiano, Memoli	Not Assigned	Not Assigned	Cyclohexylphenyl Vasopressin Agonists
10/120,917	April 11, 2002	Failli, Shumsky, Dusza, Caggiano, Memoli	Not Assigned	1614	Cyclohexylphenyl Vasopressin Agonists
10/121,156	April 11, 2002	Failli, Dusza, Caggiano, Shumsky, Memoli, Trybulski	Not Assigned	1614	Biphenyl Vasopressin Agonists
60/283,263	April 12, 2001	Failli, Disza, Caggiano, Shumsky, Memoli, Trybulski	Not Assigned	Not Assigned	Biphenyl Vasopressin Agonists
09/495,507	February 1, 2000	Steffan, Failli			Pyridobenzodiazepine and Pyridobenzoxazepine Carboxamide Vasopressin Agonists
08/903,369	July 30, 1997	Dusxa, Chan, Albright, Bagli, Failli, Ashwell, Molinari, Caggiano, Trybulski	B. Kifle	1611	Tricyclic Vasopressin Agonists
09/122,020	July 24, 1998	Dusza, Chan, Albright, Bagli, Failli, Ashwell, Moinari, Caggiano, Trybulski	B. Coleman	1624	Tricyclic Vasopressin Agonists
08/985,667	December 5, 1997	Adelman, Prozialeck	Z. Fay	1614	Use of 17 $\beta$ -Dihydroequilenin as an Antioxidant
60/388,596	June 13, 2002	Komm, Jenkins	Not Assigned	Not Assigned	Bazedoxifene Treatment Regimes
08/837,129	April 14, 1997	Miller, Tran			3-[4-(2-Phenyl-Indole-1-Ylmethyl)-Phenyl]- Acrylamides as Estrogenic Agents
09/896,361	June 29, 2001	Jenkins	W. Jarvis	1614	Combinations of SSRI and Estrogenic Agents
09/069,042	April 29, 1998	Miller, Collini, Tran	A. Messinger	1611	2-Phenyl-1-[4-(Amino-1-YL-ALK-1-Ynyl)- Benzyl]-1H-Indol-5-Ols As Estrogenic Agents



09/513,807	February 25, 2000	Koko, Ullrich, Santilli				N-Substituted Benzoyl Indoles as Estrogenic Agents
09/513,112	February 25, 2000	Ullrich	B. Coleman	1624		N-Substituted Indolines as Estrogenic Agents
09/896,353	June 29, 2001	Jenkins, Komm	R. Henley	1614		Combinations of Statins and Estrogenic Agents
10/317,163	December 11, 2002	Mewshaw, Edsall, Cohn, Harris, Keith, Albert	Not Assigned	1614		Substituted 6H-Dibenzo[c,h] Chromenes as Estrogenic Agents
10/099,361	March 15, 2002	Pickar	Not Assigned	1615		Hormone Replacement Therapy
60/369,682	April 3, 2002	Grubb, Pickar	Not Assigned	Not Assigned		Hormone Replacement Therapy
10/099,356	March 15, 2002	Pickar	S. Jiang	1617		Estrogen Replacement Therapy
10/340,425	January 10, 2003	Coghlan, Fobare, Harris, Keith, Albert	D. Lambkin	1626		Phenyl Substituted Thiophene as Estrogenic Agents
10/348,511	January 21, 2003	Harris, Henderson	Not Assigned	1614		Method of Treating Hemorrhagic Shock or Systemic Inflammatory Response Syndrome
10/316,640	December 11, 2002	Mewshaw, Edsall, Yang, Harris, Keith, Albert	Not Assigned	1614		Substituted Phenyl Naphthalenes as Estrogenic Agents
10/316,641	December 11, 2002	Malamas, Gunawan, Harris, Keith, Albert	Not Assigned	1614		Naphthyl Benzoxazoles and Benzisoxazoles and Estrogenic Agents
10/316,446	December 11, 2002	McDevitt, Harris, Keith, Albert	Not Assigned	1632		Substituted Indenones as Estrogenic Agents
10/348,510	January 21, 2003	Harris, Keith, Albert, Vid, Megati, Miller	Not Assigned	1614		6-Hydroxyequilenins as Estrogenic Agents
10/320,207	December 16, 2002	Miller, Collini, Kaufman, Morris, Singhaus, Ullrich, Harris, Keith, Albert, Unwalla	Not Assigned	1614		Substituted 2-Phenyl Benzofurans As Estrogenic Agents
10/320,761	December 16, 2002	Molinari and Trybulski	Not Assigned	Not Assigned		Biologically Active Vasopressin Agonist Metabolites
10/316,616	December 11, 2002	Malamas, Dinh, Gunawan, Collini, Harris, Keith, Albert	Not Assigned	1614		Phenyl Benzisoxaloles as Estrogenic Agents
09/432,010*	November 1,	Bemder. Fawzi,	N.S. Qazi	1616		Pregnanes

	1000	Fletcher, Morton, Shan, Tang				
60/393,424	July 2, 2002	Megati, Vid, Mohan, Ravedndranath, Potoski	Not Assigned	Not Assigned	Preparation of 6-Hydroxy-equilenins	
10/164,149*	June 5, 2002	Kagan, Raveendranath, Shah, Winkley	B. Badio	1616	B-Ring Estratriene Diols	
10/348,506*	January 21, 2003	Sha, Raveendranath, Kagan	Not Assigned	1616	B-Ring Estratrienes	
10/162,972*	June 5, 2002	Kagan, Kong, McDonald, Raveendranath, Sha, Zeldis	B. Badio	1616	Estrenes	
09/487,371*	January 18, 2000	Miller, Collini, Tran	L. Stockton	1626	Indenoindoles and benzocarbazoles as Estrogenic Agents	
09/896,226	June 29, 2001	Benjamin, dulin, Suryawanshi	S. Jiang	1617	Pharmaceutical Compositions of Estrogenic Agents	
09/659,091	September 11, 2000	Miller, Collinik Tran, Chan, Rubeshov	E. Peselev	1623	2-(4-Hydroxy-Phenyl)-3-Methyl-1-[4-(2-Amino-1-yl-Ethoxy)-Benzyl]-1H-Indol-5-Ols	
09/458,317*	December 10, 1999	Raveendranath, Zeldis, Vid, Potoski, Ren, Iera	E. Sackey	1626	Novel Aryloxy-Alkyl-Dialkylamines	
09/458,316*	December 10, 1999	Raveendranath, Zeldis, Vid, Potoski, Ren, Iera	E. Sackey	1626	Novel Aryloxy-Alkyl-Dialkylamines	
08/886,072	July 2, 1997	Gast	T. Criares	1617	Oral Contraceptive	
08/157,661	December 1, 1993	Adelman, Steiner	K. Jordan	1205	Anti-Atherosclerotic Use of 17 Alpha-Dihydroequilin	
08/000,777	January 5, 1993	Adelman, Steiner	G. Hook	1205	Anti-Atherosclerotic Use of 17 Alpha-Dihydroequiline	
08/019,387	February 18, 1993	Raveendranath and Wichtowski	B. Badio	1616	Salts of 8,9-Dehydroestrone Sulfate Ester	
07/841,694	February 26, 1992	Raveendranath and Wichtowski	K. Kestler	1206	Alkalai Metal 8, 9-Dehydroestrone Sulfate Esters	

07/984,741*	December 3, 1992	Raveendranath and Wichtowski	K. Kestler	1206	Alkalai Metal 8, 9-Dehydroewstrone Sulfate Esters
09/063,581	April 21, 1998	Bender, Fawzi, Fletcher, Morton Sha, and Tang	S/ Qazi	1616	Pregnanes
10/424,412	April 28, 2003	Pickar	Not Assigned	Not Assigned	Hormone Replacement Therapy
60/381,257	May 17, 2002	Pickar	Not Assigned	Not Assigned	Hormone Replacement Therapy
10/438,573	May 15, 2003	Pickar	Not Assigned	Not Assigned	Hormone Replacement Therapy
60/381,348	May 17, 2002	Grubb and Pickar	Not Assigned	Not Assigned	Hormone Replacement Therapy
10/438,643	May 15, 2003	Grubb and Pickar	Not Assigned	Not Assigned	Hormone Replacement Therapy
60/172,218	February 4, 1999	Steffan & Failli	Not Assigned	Not Assigned	Pyridobenzodiazepine and Pyridobenzoxazepine Carboxamide Vasopressin
29/099,540	January 22, 1999	Finkelston & Shampooe	2912	C. Rademaker	Diak Pack Tablet Dispenser
29/091,064	July 22, 1998	Finkelston & Shampooe	2912	C. Rademaker	Dial Pack Tablet Dispenser
09/064,994	April 23, 1998	Kagan & Shah	1623	M. Moran	Pregnan-3-OL-20-Ones
10/404,314	April 1, 2003	Grubb, Pickar, Constantine and Day	Not Assigned	Not assigned	Hormone Replacement Therapy
60/472,382	May 21, 2003	Harris, Quinn and Kurasch	Not Assigned	Not Assigned	Antiarthritic Combinations
09/063,451	April 21, 1998	Kagan, Raveendranath, Shah and Winkley	1616	B. Badio	B-Ring Estratriene Diols
10/404,163	April 1, 2003	Grubb, Pickar, Constantine and Dey	Not Yet Assigned	Not Yet Assigned	Hormone Replacement Therapy
10/726,168*	December 2, 2003	Abou-Gharbia, Barrett, Childers, Moyer	1614	Not Yet Assigned	Methods for Treatment and Prevention of Neurodegenerative Conditions

\* Assignment is from parent application.